| |
VA researchers develop biomed innovations in all areas of healthcare, from substance abuse treatments to visual impairment aids and more. License and commercialize VA innovations with no-cost help from TechLink. Learn about available technologies. 
|
|
Today’s Big NewsJul 25, 2024 |
| By Nick Paul Taylor Roche has punted a Pompe disease gene therapy from its pipeline after weighing up the competitive landscape. The Swiss drugmaker made the change in a second-quarter update that also featured news of TIGIT trial closures and a commitment not to make “huge cuts” to the organization. |
|
|
|
By Gabrielle Masson AbbVie is discontinuing solo development of a midstage Alzheimer’s disease candidate, a monoclonal antibody that failed to differentiate itself against already approved treatments. |
By James Waldron Sanofi has halted work on a phase 2 candidate for a rare growth disorder as part of a pipeline clear out that saw the French pharma discontinue two other rare disease assets and one of its mRNA flu vaccines. |
Sponsored by CSafe Global How is the cold chain adapting to the cell and gene therapy boom? Emilio Frattaruolo, Vice President of Cell and Gene Therapies at CSafe, discusses the logistical challenges and innovations shaping the future of these revolutionary treatments. |
|
Cryoport Systems' temperature-controlled supply chain solutions, including biostorage, drug labelling, kit production, cryopreservation & consulting were built with scalability in mind, Enabling The Outcome™️ for patients around the world. Learn More. 
|
|
By Annalee Armstrong Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million. |
Sponsored by InMed Pharmaceuticals InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease |
By Nick Paul Taylor Chemomab Therapeutics has shared phase 2 results it claims show CM-101 is a triple threat in primary sclerosing cholangitis, simultaneously tackling fibrosis, inflammation and cholestasis. But the pitch fell flat with investors, who sent the biotech’s stock down around 18% when the market opened. |
By Fraiser Kansteiner While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus drug, the near-term expected approval of a pair of new filling lines is giving the French pharma assurance that its AstraZeneca-partnered antibody Beyfortus can breach the billion-dollar threshold before the year is out. |
By Darren Incorvaia Autobahn Labs is speeding towards success thanks to a new partnership with Charles River Laboratories. According to a Wednesday release, Autobahn, a virtual biotech accelerator, will gain access to Charles River’s drug development capabilities. |
By Angus Liu Among AstraZeneca's growth drivers with $5 billion or more in peak sales potential, the company is counting on Daiichi Sankyo-partnered Enhertu to chart new territory. And stalling sales underscore the challenges facing the HER2 drug. |
By Paige Minemyer The Centers for Medicare & Medicaid Services has released new data on risk adjustment payments for 2023. |
Fierce podcasts Don’t miss an episode |
| In February, Novo Holdings announced a $16.5 billion deal to acquire Catalent, and this week on "The Top Line," we explore the current state and implications of the proposed buyout. |
|
|---|
|
|
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today! 
|
|
Whitepaper Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
